Developer docs
API playgroundTry for free, no card

Search company profiles

Seqvera

Full company profile

uuid002bqqx

Namestring
Seqvera
Legal namestring
Seqvera Ltd. Oy
Websiteurl
seqvera.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Seqvera Ltd. Oy is a Finnish private limited company headquartered in Helsinki's Terkko Health Hub that provides specialized testing, validation, and analytical services for biomaterials, medical devices, pharmaceutical products, advanced therapy medicinal products (ATMPs), substances of human origin (SoHO), and 3D bioprinted constructs. The company was established to commercialize BEST (Biomaterials Enhanced Simulation Testing), a patented methodology portfolio that combines coherent physiological stimulation with idempotent mathematical analysis to generate model-free, clinically relevant data for material behavior prediction. Its intellectual property includes granted US patents on injectability testing (US10,809,171 B2), biomaterials testing (US10,379,106 B2), and auto-mechano-induction in cell development, plus a patent-pending Drug Transport Signature (DTS) method. Seqvera operates as a boutique professional services provider with non-public, customized pricing and NDA-protected engagements, primarily targeting enterprise medical device, biomaterials, and pharmaceutical developers. Its commercial visibility is anchored by EU research project participation (LIFESAVER under Horizon 2020, CARE-IN-HEALTH under Horizon Europe), scientific conference presence, and a documented collaboration with Askel Healthcare Ltd. on dental abutment optimization. The company is privately held with no disclosed investors, parent, or external funding rounds.

Short descriptiontext

Seqvera Ltd. Oy is a Finnish specialist services firm that provides BEST (Biomaterials Enhanced Simulation Testing), a patented methodology for physiologically relevant testing and validation of biomaterials, medical devices, and pharmaceutical products. It serves enterprise healthtech, medtech, and pharmaceutical developers seeking MDR-compliant data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomaterials testing, medical device validation, biomedical testing services, injectability testing, biomaterials characterization
NAICS code1 code
  • Testing Laboratories and Services541380
SIC code2 codes
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Biomedical Testing and Validation Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Testing and Analysis Services
TypeProfessional Services
Description

Seqvera provides solutions for design, development, testing and validation of biomaterials, medical devices and other products. Services include coherent testing, idempotent analysis, and model-free data extraction for optimization of biomedical solutions.

seqvera.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1BEST (Biomaterials Enhanced Simulation Testing)
Description

The core patented methodology for testing biomaterials, medical devices, tissues, and injectable hydrogels under physiologically relevant conditions to generate model-free data for material optimization and behavior prediction.

seqvera.com
Core offering1 text field

Seqvera provides testing and validation services for biomaterials, medical devices, medicinal products, ATMP/SoHO applications, and 3D bioprinted products using its patented BEST (Biomaterials Enhanced Simulation Testing) methodology. The company delivers coherent stimulation testing combined with idempotent analysis to produce model-free data under physiologically relevant conditions, supporting regulatory compliance with MDR 2017/745 and 3R principles. Services include tailored analysis, retrospective data reprocessing, and SOP development assistance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Shortens time and costs of materials development and optimization
+3 more records
Product overview1 text field

Seqvera offers a single unified product/service centered on BEST (Biomaterials Enhanced Simulation Testing) - a patented methodology comprising several patented techniques for tailored and integrated analysis of materials, tissues, devices, and injectable hydrogels. The BEST approach combines coherent stimulation testing with idempotent analysis to generate model-free data. Services include both pro- and retrospective data analysis, SOP development assistance, and regulatory compliance support for medical devices, biomaterials, ATMP/SoHO products, and 3D bioprinted products under MDR 2017/745.

Product and service1 record
1BEST (Biomaterials Enhanced Simulation Testing)
Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EU Horizon 2020 project addressing unmet needs in creating a valid scientific knowledge base for development and implementation of regulatory approaches relevant to maternal and fetal health. It aims to generate and validate effects data of environmental pollutants and pharma treatments for pregnant women. Grant Agreement No 101036702.

2CARE-IN-HEALTH
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cardiovascular Resolution of Inflammation to promote Health project addressing chronic inflammation during transition from health to cardiovascular disease. Funded under EU Horizon Europe program, Grant Agreement No 101095413.

seqvera.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration where BEST method was used to generate valuable data for development of new dental abutments. Quote from CTO: 'The BEST method has given us valuable data which we would not be able to get otherwise.'

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1NAMSA
TypeDirect peer
Description

World's largest medical device-focused CRO, offering biological, toxicology, and materials testing services to medical device manufacturers. Directly comparable to Seqvera as a regulatory-aligned, biomaterials-and-medical-device testing provider serving compliance-driven workflows.

TypeBroad incumbent
Description

Global CRO/CDMO providing laboratory testing, bioanalysis, and medical device testing services. Comparable to Seqvera's biomaterials and medical device testing offering, scaled to a much larger diversified platform.

TypeBroad incumbent
Description

Global quality assurance and testing company with strong medical device and pharmaceutical testing offerings. Comparable to Seqvera across multiple testing verticals, but at much larger scale and broader service portfolio.

TypeBroad incumbent
Description

Global testing, inspection, and certification company with a dedicated life sciences / medical device testing portfolio. Comparable to Seqvera as a regulatory-anchored testing provider for medical device manufacturers and pharma companies.

TypeDirect peer
Description

Specialized medical device and pharmaceutical testing laboratory, now part of Fortrea (formerly LabCorp Drug Development). Directly comparable to Seqvera in delivering preclinical and biocompatibility-focused testing for medical devices.

TypeBroad incumbent
Description

Large global CRO offering preclinical, biomedical, and medical device testing services. Comparable to Seqvera as a comprehensive testing partner for medical device and drug developers, though much broader and with significantly greater scale.

TypeDirect peer
Description

Specialized laboratory testing services for medical devices and pharmaceutical companies, with focus on sterility, biocompatibility, and packaging. Comparable to Seqvera in delivering device/biomaterials testing that supports MDR and FDA compliance.

8TÜV SÜD
TypeBroad incumbent
Description

Global certification and testing body with strong medical device testing and MDR compliance services. Comparable to Seqvera in providing MDR-aligned testing and validation for medical device manufacturers in Europe.

TypeBroad incumbent
Description

Standards and certification body with medical device testing and notified body services. Comparable to Seqvera as a compliance-focused testing/validation partner for medical device companies operating under MDR.

TypeBroad incumbent
Description

Global testing services group operating across pharmaceutical, medical device, and biomaterials testing. Relevant as a competitor offering laboratory testing and validation services across Seqvera's target verticals, though at vastly larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seqvera

Biomedical Testing and Validation Servicesseqvera.com

Seqvera Ltd. Oy is a Finnish specialist services firm that provides BEST (Biomaterials Enhanced Simulation Testing), a patented methodology for physiologically relevant testing and validation of biomaterials, medical devices, and pharmaceutical products. It serves enterprise healthtech, medtech, and pharmaceutical developers seeking MDR-compliant data.

What Seqvera does

Seqvera Ltd. Oy is a Finnish private limited company headquartered in Helsinki's Terkko Health Hub that provides specialized testing, validation, and analytical services for biomaterials, medical devices, pharmaceutical products, advanced therapy medicinal products (ATMPs), substances of human origin (SoHO), and 3D bioprinted constructs. The company was established to commercialize BEST (Biomaterials Enhanced Simulation Testing), a patented methodology portfolio that combines coherent physiological stimulation with idempotent mathematical analysis to generate model-free, clinically relevant data for material behavior prediction. Its intellectual property includes granted US patents on injectability testing (US10,809,171 B2), biomaterials testing (US10,379,106 B2), and auto-mechano-induction in cell development, plus a patent-pending Drug Transport Signature (DTS) method. Seqvera operates as a boutique professional services provider with non-public, customized pricing and NDA-protected engagements, primarily targeting enterprise medical device, biomaterials, and pharmaceutical developers. Its commercial visibility is anchored by EU research project participation (LIFESAVER under Horizon 2020, CARE-IN-HEALTH under Horizon Europe), scientific conference presence, and a documented collaboration with Askel Healthcare Ltd. on dental abutment optimization. The company is privately held with no disclosed investors, parent, or external funding rounds.

Seqvera firmographics

Firmographics
Name
Seqvera
Legal name
Seqvera Ltd. Oy
Website
https://seqvera.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Seqvera Ltd. Oy is a Finnish specialist services firm that provides BEST (Biomaterials Enhanced Simulation Testing), a patented methodology for physiologically relevant testing and validation of biomaterials, medical devices, and pharmaceutical products. It serves enterprise healthtech, medtech, and pharmaceutical developers seeking MDR-compliant data.
Ownership category
akta.pro rank

Where Seqvera is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Seqvera business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Testing and Analysis Services: Seqvera provides solutions for design, development, testing and validation of biomaterials, medical devices and other products. Services include coherent testing, idempotent analysis, and model-free data extraction for optimization of biomedical solutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Seqvera product offering

Product offering

Core offering

Seqvera provides testing and validation services for biomaterials, medical devices, medicinal products, ATMP/SoHO applications, and 3D bioprinted products using its patented BEST (Biomaterials Enhanced Simulation Testing) methodology. The company delivers coherent stimulation testing combined with idempotent analysis to produce model-free data under physiologically relevant conditions, supporting regulatory compliance with MDR 2017/745 and 3R principles. Services include tailored analysis, retrospective data reprocessing, and SOP development assistance.

Product overview

Seqvera offers a single unified product/service centered on BEST (Biomaterials Enhanced Simulation Testing) - a patented methodology comprising several patented techniques for tailored and integrated analysis of materials, tissues, devices, and injectable hydrogels. The BEST approach combines coherent stimulation testing with idempotent analysis to generate model-free data. Services include both pro- and retrospective data analysis, SOP development assistance, and regulatory compliance support for medical devices, biomaterials, ATMP/SoHO products, and 3D bioprinted products under MDR 2017/745.

Differentiator

Problem solved

Functional benefit

Brands

  • BEST (Biomaterials Enhanced Simulation Testing): The core patented methodology for testing biomaterials, medical devices, tissues, and injectable hydrogels under physiologically relevant conditions to generate model-free data for material optimization and behavior prediction.

Products and services

  • BEST (Biomaterials Enhanced Simulation Testing)

Quantifiable outcome

  • Shortens time and costs of materials development and optimization
  • +3 more outcomes

Companies that use Seqvera

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Seqvera technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Seqvera partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • LIFESAVER ProjectcoreStrategic or Co-development PartnerEU Horizon 2020 project addressing unmet needs in creating a valid scientific knowledge base for development and implementation of regulatory approaches relevant to maternal and fetal health. It aims to generate and validate effects data of environmental pollutants and pharma treatments for pregnant women. Grant Agreement No 101036702.
  • CARE-IN-HEALTHcoreStrategic or Co-development PartnerCardiovascular Resolution of Inflammation to promote Health project addressing chronic inflammation during transition from health to cardiovascular disease. Funded under EU Horizon Europe program, Grant Agreement No 101095413.
  • Askel Healthcare Ltd.minorStrategic or Co-development PartnerCollaboration where BEST method was used to generate valuable data for development of new dental abutments. Quote from CTO: 'The BEST method has given us valuable data which we would not be able to get otherwise.'

Recent moves5 records

Expansion highlights5 records

Seqvera competitors and assessment

Company assessment

Direct peers

  • NAMSA: World's largest medical device-focused CRO, offering biological, toxicology, and materials testing services to medical device manufacturers. Directly comparable to Seqvera as a regulatory-aligned, biomaterials-and-medical-device testing provider serving compliance-driven workflows.
  • Toxikon (LabCorp / Fortrea): Specialized medical device and pharmaceutical testing laboratory, now part of Fortrea (formerly LabCorp Drug Development). Directly comparable to Seqvera in delivering preclinical and biocompatibility-focused testing for medical devices.
  • Nelson Labs (Sotera Health): Specialized laboratory testing services for medical devices and pharmaceutical companies, with focus on sterility, biocompatibility, and packaging. Comparable to Seqvera in delivering device/biomaterials testing that supports MDR and FDA compliance.

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO providing laboratory testing, bioanalysis, and medical device testing services. Comparable to Seqvera's biomaterials and medical device testing offering, scaled to a much larger diversified platform.
  • Intertek: Global quality assurance and testing company with strong medical device and pharmaceutical testing offerings. Comparable to Seqvera across multiple testing verticals, but at much larger scale and broader service portfolio.
  • SGS: Global testing, inspection, and certification company with a dedicated life sciences / medical device testing portfolio. Comparable to Seqvera as a regulatory-anchored testing provider for medical device manufacturers and pharma companies.
  • Charles River Laboratories: Large global CRO offering preclinical, biomedical, and medical device testing services. Comparable to Seqvera as a comprehensive testing partner for medical device and drug developers, though much broader and with significantly greater scale.
  • TÜV SÜD: Global certification and testing body with strong medical device testing and MDR compliance services. Comparable to Seqvera in providing MDR-aligned testing and validation for medical device manufacturers in Europe.
  • BSI Group: Standards and certification body with medical device testing and notified body services. Comparable to Seqvera as a compliance-focused testing/validation partner for medical device companies operating under MDR.
  • Eurofins Scientific: Global testing services group operating across pharmaceutical, medical device, and biomaterials testing. Relevant as a competitor offering laboratory testing and validation services across Seqvera's target verticals, though at vastly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Seqvera social profiles

Digital presence

Seqvera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seqvera leadership team

Management profile

Number of profiles

Seqvera funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seqvera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seqvera

What does Seqvera do?

Seqvera provides testing and validation services for biomaterials, medical devices, medicinal products, ATMP/SoHO applications, and 3D bioprinted products using its patented BEST (Biomaterials Enhanced Simulation Testing) methodology. The company delivers coherent stimulation testing combined with idempotent analysis to produce model-free data under physiologically relevant conditions, supporting regulatory compliance with MDR 2017/745 and 3R principles. Services include tailored analysis, retrospective data reprocessing, and SOP development assistance.

Is Seqvera a public or private company?

Seqvera is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Seqvera founded?

Seqvera was founded in 2016. It employs 1 to 10 people.

Where is Seqvera based?

Seqvera is headquartered in Helsinki, Finland, in the Europe region.

How does Seqvera make money?

One revenue line is on record: testing and Analysis Services.

Who are Seqvera's main competitors?

Direct peers on record are NAMSA, Toxikon (LabCorp / Fortrea) and Nelson Labs (Sotera Health). Broad incumbents are WuXi AppTec, Intertek, SGS, Charles River Laboratories, TÜV SÜD, BSI Group and Eurofins Scientific.

Does Seqvera have an API?

No public API is recorded for Seqvera.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales